These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 12833457

  • 1. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study.
    Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Bock JE, Glud E, Nørgaard-Pedersen B, Høgdall CK.
    Cancer; 2003 Jul 01; 98(1):66-73. PubMed ID: 12833457
    [Abstract] [Full Text] [Related]

  • 2. Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the Danish "MALOVA" Ovarian Carcinoma Study.
    Høgdall EV, Ryan A, Kjaer SK, Blaakaer J, Christensen L, Bock JE, Glud E, Jacobs IJ, Høgdall CK.
    Cancer; 2004 Jun 01; 100(11):2387-95. PubMed ID: 15160342
    [Abstract] [Full Text] [Related]

  • 3. Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer: from the Danish "MALOVA" ovarian cancer study.
    Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Christensen IJ, Gayther S, Jacobs IJ, Høgdall CK.
    Gynecol Oncol; 2007 Aug 01; 106(2):318-24. PubMed ID: 17540436
    [Abstract] [Full Text] [Related]

  • 4. The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study.
    Riener EK, Arnold N, Kommoss F, Lauinger S, Pfisterer J.
    Gynecol Oncol; 2004 Oct 01; 95(1):89-94. PubMed ID: 15385115
    [Abstract] [Full Text] [Related]

  • 5. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
    Høgdall EV, Christensen L, Høgdall CK, Blaakaer J, Gayther S, Jacobs IJ, Christensen IJ, Kjaer SK.
    Oncol Rep; 2007 Nov 01; 18(5):1051-9. PubMed ID: 17914554
    [Abstract] [Full Text] [Related]

  • 6. c-erbB-2, p53, and nm23 proteins as prognostic factors in patients with epithelial ovarian carcinoma.
    Tomić S, Ilić Forko J, Babić D, Sundov D, Kuret S, Andelinović S.
    Croat Med J; 2003 Aug 01; 44(4):429-34. PubMed ID: 12950146
    [Abstract] [Full Text] [Related]

  • 7. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1.
    Chambers SK, Kacinski BM, Ivins CM, Carcangiu ML.
    Clin Cancer Res; 1997 Jun 01; 3(6):999-1007. PubMed ID: 9815777
    [Abstract] [Full Text] [Related]

  • 8. Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma.
    Tanabe H, Nishii H, Sakata A, Suzuki K, Mori Y, Shinozaki H, Watanabe A, Ochiai K, Yasuda M, Tanaka T.
    Gynecol Oncol; 2004 Sep 01; 94(3):735-9. PubMed ID: 15350366
    [Abstract] [Full Text] [Related]

  • 9. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study.
    Høgdall EV, Christensen L, Kjaer SK, Blaakaer J, Kjaerbye-Thygesen A, Gayther S, Jacobs IJ, Høgdall CK.
    Gynecol Oncol; 2007 Mar 01; 104(3):508-15. PubMed ID: 17113137
    [Abstract] [Full Text] [Related]

  • 10. Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma.
    Ardizzoni A, Cafferata MA, Paganuzzi M, Filiberti R, Marroni P, Neri M, Fontana V, Nicoló G, Perdelli L, Stampino CG, Rosso R, Puntoni R.
    Cancer; 2001 Oct 01; 92(7):1896-904. PubMed ID: 11745263
    [Abstract] [Full Text] [Related]

  • 11. Effect of HER-2/neu overexpression on chemoresistance and prognosis in ovarian carcinoma.
    Sasaki N, Kudoh K, Kita T, Tsuda H, Furuya K, Kikuchi Y.
    J Obstet Gynaecol Res; 2007 Feb 01; 33(1):17-23. PubMed ID: 17212661
    [Abstract] [Full Text] [Related]

  • 12. [Relationship between expressions of p53, c-erbB2 genes, proliferating cell nuclear antigen and prognosis of patients with ovarian epithelial carcinoma].
    Li JD, Li MD, Li YF, Huang X, Liu JH, Liu FY, Zhang CQ.
    Ai Zheng; 2002 Mar 01; 21(3):292-6. PubMed ID: 12451998
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer.
    Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, Baselga J, Ramon y Cajal S.
    Cancer; 2006 Oct 15; 107(8):1801-11. PubMed ID: 16983702
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. P53 mutations in tissue from Danish ovarian cancer patients: from the Danish "MALOVA" ovarian cancer study.
    Høgdall EV, Kjaer SK, Blaakaer J, Christensen L, Glud E, Vuust J, Høgdall CK.
    Gynecol Oncol; 2006 Jan 15; 100(1):76-82. PubMed ID: 16183105
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.